Jeb Bush, Governor of the US state of Florida, has now signed into lawlegislation allowing generics rated AB by the US Food and Drug Administration to be substituted for brand-name products (Marketletters passim).
Bill HB69, which the legislature approved overwhelmingly, could save Florida consumers up to $20 million a year, said Barr Labs' chairman Bruce Downey. The bill removes the restrictions on Barr's generic version of DuPont's anticoagulant Coumadin (warfarin), a drug which consumers in Florida alone spend about $40 million a year on, with over half paying out-of-pocket, he said. DuPont opposed the change.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze